{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:40:26Z","timestamp":1792896026286,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T00:00:00Z","timestamp":1777161600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["NCT05155254"],"award-info":[{"award-number":["NCT05155254"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.annonc.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:37:09Z","timestamp":1776814629000},"page":"999-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma"],"prefix":"10.1016","volume":"37","author":[{"given":"J.C.","family":"Hassel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8322-475X","authenticated-orcid":false,"given":"P.A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8920-5429","authenticated-orcid":false,"given":"P.","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Coetzee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Puzanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.B.","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Poklepovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Amaral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vedel Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5968-3000","authenticated-orcid":false,"given":"A.","family":"Wakatsuki Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Zocca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ringeisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-6037","authenticated-orcid":false,"given":"I.M.","family":"Svane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.annonc.2026.04.010_bib1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.010_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2026.04.010_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.010_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2026.04.010_bib5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","volume":"35","author":"Long","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.010_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00281-022-00966-0","article-title":"Tumor microenvironment antigens","volume":"45","author":"Andersen","year":"2023","journal-title":"Semin Immunopathol"},{"issue":"7","key":"10.1016\/j.annonc.2026.04.010_bib7","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1182\/blood-2010-06-288498","article-title":"Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators","volume":"117","author":"S\u00f8rensen","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.annonc.2026.04.010_bib8","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1158\/0008-5472.CAN-12-3507","article-title":"HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients","volume":"73","author":"Munir","year":"2013","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2026.04.010_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000605","article-title":"Peptide vaccination directed against IDO1-expressing immune cells elicits CD8(+) and CD4(+) T-cell-mediated antitumor immunity and enhanced anti-PD1 responses","volume":"8","author":"Dey","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.annonc.2026.04.010_bib10","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1038\/s41591-021-01544-x","article-title":"A phase 1\/2 trial of an immune-modulatory vaccine against IDO\/PD-L1 in combination with nivolumab in metastatic melanoma","volume":"27","author":"Kjeldsen","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.010_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/2326-6066.CIR-21-0457","article-title":"IDO vaccine ablates immune-suppressive myeloid populations and enhances antitumor effects independent of tumor cell IDO status","volume":"10","author":"Nandre","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"Suppl 1","key":"10.1016\/j.annonc.2026.04.010_bib12","article-title":"1468 Peptide vaccination against PD-L1 reduces tumor growth in preclinical models through stimulation of PD-L1-targeting T cells in the tumor microenvironment","volume":"11","author":"Chapellier","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"8_Supplement_1","key":"10.1016\/j.annonc.2026.04.010_bib13","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2025-2241","article-title":"Abstract 2241: Immune-modulatory therapeutic cancer vaccines against IDO1 and PD-L1 control tumor growth through target specific changes in the tumor microenvironment","volume":"85","author":"Chapellier","year":"2025","journal-title":"Cancer Res"},{"issue":"Suppl 6","key":"10.1016\/j.annonc.2026.04.010_bib14","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1158\/1538-7445.AM2024-4094","article-title":"Abstract 4094: Immune modulatory cancer vaccines against IDO1 and PD-L1 trigger distinct pathways and cooperatively reduce tumor growth in preclinical models","volume":"84","author":"Chapellier","year":"2024","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.annonc.2026.04.010_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006755","article-title":"Long-term follow-up of anti-PD-1 na\u00efve patients with metastatic melanoma treated with IDO\/PD-L1 targeting peptide vaccine and nivolumab","volume":"11","author":"Lorentzen","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.010_bib16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2018.1489246","article-title":"The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care","volume":"18","author":"Keung","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"34","key":"10.1016\/j.annonc.2026.04.010_bib17","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.04.010_bib18","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.humimm.2004.06.006","article-title":"Optimization of an elispot assay to detect cytomegalovirus-specific CD8+ T lymphocytes","volume":"65","author":"Godard","year":"2004","journal-title":"Hum Immunol"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.010_bib19","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00262-004-0578-9","article-title":"Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients","volume":"54","author":"Meier","year":"2005","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"10.1016\/j.annonc.2026.04.010_bib20","doi-asserted-by":"crossref","first-page":"5907","DOI":"10.4049\/jimmunol.180.9.5907","article-title":"HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals","volume":"180","author":"Calarota","year":"2008","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.annonc.2026.04.010_bib21","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.annonc.2026.04.010_bib22","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.21.00079","article-title":"Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2026.04.010_bib23","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma","volume":"41","author":"Robert","year":"2023","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2026.04.010_bib24","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2026.04.010_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2217\/mmt-2016-0013","article-title":"PD-L1 in melanoma: facts and myths","volume":"3","author":"Mandal\u00e0","year":"2016","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.annonc.2026.04.010_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115547","article-title":"Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update","volume":"225","author":"Lipson","year":"2025","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2026.04.010_bib27","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade: advances in molecular mechanisms and therapeutic strategies","volume":"6","author":"Gao","year":"2025","journal-title":"MedComm (2020)"},{"issue":"10","key":"10.1016\/j.annonc.2026.04.010_bib28","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1007\/s00262-010-0875-4","article-title":"Response definition criteria for ELISPOT assays revisited","volume":"59","author":"Moodie","year":"2010","journal-title":"Cancer Immunol Immunother"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426001511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:42:01Z","timestamp":1785876121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426001511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0923753426001511"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.010","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}